Top 5 Physical Rehabilitation Apps for Primary Care Providers

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Novel Neurostimulation Device Shows Significant Benefit for Migraine

Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance

Telehealth Certification Program Offered by the American Heart Association

Daily Dose: Flash CGM Improves Glycemic Control in Patients with T2D Using Noninsulin Therapies

Daily Dose: More Steps a Day Linked to Better Health for Patients with Heart Failure

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Novel Neurostimulation Device Shows Significant Benefit for Migraine

Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance

Telehealth Certification Program Offered by the American Heart Association

Daily Dose: Flash CGM Improves Glycemic Control in Patients with T2D Using Noninsulin Therapies

Daily Dose: More Steps a Day Linked to Better Health for Patients with Heart Failure

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Novel Neurostimulation Device Shows Significant Benefit for Migraine

Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance

Telehealth Certification Program Offered by the American Heart Association

Daily Dose: Flash CGM Improves Glycemic Control in Patients with T2D Using Noninsulin Therapies

Daily Dose: More Steps a Day Linked to Better Health for Patients with Heart Failure

Related Content

Oral Superabsorbent Hydrogel Cuts Risk for Type 2 Diabetes

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Your daily dose of clinical news you may have missed.

Novel Neurostimulation Device Shows Significant Benefit for Migraine

Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance

The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.

Telehealth Certification Program Offered by the American Heart Association

AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.

Daily Dose: Flash CGM Improves Glycemic Control in Patients with T2D Using Noninsulin Therapies

The certification is available to all health care professionals and aims to standardize training and increase skills in telehealth care delivery and integration into practice.